NanoTemper Technologies, maker of life science tools for protein characterization, has launched its newest system, Dianthus, at the Society for Laboratory Automation and Screening (SLAS2019) conference in Washington, DC. Built to address the demands of drug discovery screening, Dianthus removes the complexity of binding interaction measurements and enables scientists to develop new drugs for every target faster and at lower costs.
Get fast, non-stop, highly sensitive hit screening with Dianthus. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to picomolar Kds, all by consuming the smallest amount of your target and library compounds. There's no fluidics which means no regular maintenance and no downtime. With Dianthus, get the fastest time to meaningful results with no immobilization required, because you demand it.
"There are two major challenges in drug discovery screening — the need to screen not only more molecules but more diverse ones covering a greater chemical space, and the need to address smaller projects with explorative targets," says Stefan Duhr, CEO of NanoTemper. "Dianthus has the flexibility to address both of these challenges."
Dianthus quickly identifies and ranks hits by quantifying molecular interactions in solution. It does this for any target type in any buffer or bioliquid and measures a wide range of interactions from millimolar down to picomolar Kds, all by consuming the smallest amount of your target and library compounds.
"Speed is a huge advantage and Dianthus is really fast, screening 10,000 compounds per day, which is unmatched in biophysical drug discovery," says Amit Gupta, Product Manager at NanoTemper. "That's only possible because it's very hands-off, with no fluidics so there's no cleaning or rinsing and virtually no downtime. It also uses industry-standard SBS microplates, so it easily integrates into a variety of automation workflows."